Baba H, Tsujitani S, Korenaga D, Kakeji Y, Haraguchi M, Konoe S, Maehara Y, Sugimachi K
Dept. of Surgery II, Faculty of Medicine, Kyushu University.
Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 2):1596-9.
Protective effect of OK-432 on peritoneal recurrence was examined in an experimental mouse model with Meth A fibrosarcoma injected into both abdominal wall and intraperitoneal cavity. OK-432 was given through either intratumoral (i.t.), intradermal (i.d.), intraperitoneal (i.p.), or i.p. + i.t. route. A significant antitumor effect against abdominal tumor was observed in mice given i.t. or i.p. + i.t. injection of OK-432. A significant protective effect against peritoneal recurrence and prolonged survival time was obtained in an i.p. + i.t. group, although other treatment groups showed only minimal effect. We conclude that combined i.p. and i.t. administration of OK-432 may prevent peritoneal recurrence and lead to prolongation in clinical patients with advanced GI tract cancer.
在将Meth A纤维肉瘤注射到腹壁和腹腔的实验小鼠模型中，研究了OK - 432对腹膜复发的保护作用。OK - 432通过瘤内（i.t.）、皮内（i.d.）、腹腔内（i.p.）或腹腔内 + 瘤内（i.p. + i.t.）途径给药。接受瘤内或腹腔内 + 瘤内注射OK - 432的小鼠对腹部肿瘤有显著的抗肿瘤作用。腹腔内 + 瘤内组对腹膜复发有显著的保护作用并延长了生存时间，尽管其他治疗组仅有极小的作用。我们得出结论，腹腔内和瘤内联合给予OK - 432可能预防晚期胃肠道癌临床患者的腹膜复发并延长生存期。
